ATE291614T1 - Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen - Google Patents

Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen

Info

Publication number
ATE291614T1
ATE291614T1 AT95930787T AT95930787T ATE291614T1 AT E291614 T1 ATE291614 T1 AT E291614T1 AT 95930787 T AT95930787 T AT 95930787T AT 95930787 T AT95930787 T AT 95930787T AT E291614 T1 ATE291614 T1 AT E291614T1
Authority
AT
Austria
Prior art keywords
macrophages
clonal
cancerous
cell proliferative
diagnosis
Prior art date
Application number
AT95930787T
Other languages
English (en)
Inventor
Michael S Mcgrath
Brian Herndier
Bruce Shiramizu
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/286,745 external-priority patent/US5580715A/en
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE291614T1 publication Critical patent/ATE291614T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/702Specific hybridization probes for retroviruses
    • C12Q1/703Viruses associated with AIDS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/5055Cells of the immune system involving macrophages
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/81Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
AT95930787T 1994-08-05 1995-08-01 Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen ATE291614T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/286,745 US5580715A (en) 1994-08-05 1994-08-05 Diagnosis of cancer having clonal macrophage involvement
US08/473,040 US5639600A (en) 1994-08-05 1995-06-06 Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
PCT/US1995/009715 WO1996004019A1 (en) 1994-08-05 1995-08-01 Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement

Publications (1)

Publication Number Publication Date
ATE291614T1 true ATE291614T1 (de) 2005-04-15

Family

ID=26964048

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95930787T ATE291614T1 (de) 1994-08-05 1995-08-01 Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen

Country Status (8)

Country Link
US (1) US5639600A (de)
EP (1) EP0772456B1 (de)
JP (1) JPH10503656A (de)
AT (1) ATE291614T1 (de)
AU (1) AU700490B2 (de)
CA (1) CA2196776A1 (de)
DE (1) DE69534100T2 (de)
WO (1) WO1996004019A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140098A (en) * 1996-08-30 2000-10-31 Schering Corporation Nucleic acids encoding mammalian proteinases; related reagents
CA2268069A1 (en) * 1996-10-04 1998-04-09 Chronix Biomedical Diagnostic detection of nucleic acids
US7087648B1 (en) * 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
US8198334B2 (en) * 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
KR20020091170A (ko) * 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 B 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-cd20의 조합된 사용
WO2003003975A2 (en) * 2001-06-04 2003-01-16 The General Hospital Corporation Detection and therapy of vulnerable plaque with photodynamic compounds
US20030064965A1 (en) * 2001-10-02 2003-04-03 Jacob Richter Method of delivering drugs to a tissue using drug-coated medical devices
US20030186246A1 (en) * 2002-03-28 2003-10-02 Willey James C. Multiplex standardized reverse transcriptase-polymerase chain reacton method for assessment of gene expression in small biological samples
NO326130B1 (no) * 2002-10-08 2008-10-06 Enok Tjotta Fremgangsmate for seleksjon og testing av forbindelser som inhiberer eller stimulerer klonal cellevekst
EP1864127A4 (de) * 2005-03-30 2008-07-16 Yeda Res & Dev Verfahren und systeme zur erzeugung eines zellinienstammbaums von mehreren zellproben
CN101300004B (zh) * 2005-09-23 2013-08-21 帕瑟洛吉卡有限公司 使用多胺类似物治疗病毒感染的方法
US20070202515A1 (en) * 2005-10-12 2007-08-30 Pathologica, Llc. Promac signature application
WO2008019139A2 (en) 2006-08-04 2008-02-14 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
HUE033487T2 (en) 2007-03-09 2017-12-28 Pathologica Llc MGBG for osteopontin control and multiple sclerosis treatment
WO2010003118A1 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
DK2453886T3 (en) 2009-07-16 2019-03-25 Pathologica Llc ORGANIC ADMINISTRATION COMPREHENSIVE MGBG AND DISEASE METHODS
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CA2797694A1 (en) 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Activators of human pyruvate kinase
US8858991B2 (en) 2011-01-19 2014-10-14 Pathologica Llc Delayed release oral pharmaceutical dosage forms comprising MGBG
WO2012112245A1 (en) 2011-02-14 2012-08-23 Beth Israel Deaconess Medical Center, Inc. Modulation of phosphatidylinositol-5-phosphate-4-kinase activity
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
AU2014205529B2 (en) 2013-01-08 2018-08-09 Pathologica Llc Methods and compositions for treatment of demyelinating diseases
WO2017044720A1 (en) 2015-09-11 2017-03-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
SI3364958T1 (sl) 2015-10-23 2023-05-31 Navitor Pharmaceuticals, Inc. Modulatorji interakcije sestrina in gator2 ter njihova uporaba
EP3389664A4 (de) 2015-12-14 2020-01-08 Raze Therapeutics Inc. Koffeininhibitoren von mthfd2 und verwendungen dafür
EP4234552A3 (de) 2016-03-09 2023-10-18 Raze Therapeutics, Inc. 3-phosphoglycerat-dehydrogenase-inhibitoren und verwendungen davon
PL3884939T3 (pl) 2016-03-09 2024-02-26 Raze Therapeutics, Inc. Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
WO2018089499A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
US11091451B2 (en) 2016-12-05 2021-08-17 Raze Therapeutics, Inc. SHMT inhibitors and uses thereof
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
ES3040534T3 (en) 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
WO2019109046A1 (en) 2017-11-30 2019-06-06 Arrakis Therapeutics, Inc. Nucleic acid-binding photoprobes and uses thereof
GB2585152A (en) * 2018-02-27 2020-12-30 The Board Of Trustees Of The Leland Standford Junior Univ Engineered immune cells as diagnostic probes of disease
BR112020025283A2 (pt) 2018-06-15 2021-03-09 Navitor Pharmaceuticals, Inc. Análogos de rapamicina e usos dos mesmos
CA3117336A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1
IL292612A (en) 2019-11-01 2022-07-01 Navitor Pharm Inc Treatment methods using mtorc1 modulator
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4681840A (en) * 1984-01-18 1987-07-21 The United States Of America As Represented By The Secretary Of Commerce Deoxyribonucleic acid molecules useful as probes for detecting oncogenes incorporated into chromosomal DNA
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5177192A (en) * 1987-04-02 1993-01-05 Centocor, Incorporated Method for labeling antibodies with a metal ion
US4795739A (en) * 1987-05-29 1989-01-03 Gene Labs, Inc. Method of inhibiting HIV
US4869903A (en) * 1987-05-29 1989-09-26 Genelabs Incorporated Method of selectively inhibiting HIV
US5180816A (en) * 1988-08-24 1993-01-19 Centocor One vial method for labeling protein/linker conjugates with technetium-99M
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
EP0567575B1 (de) * 1991-01-14 1999-10-13 New York University Cytokin-induziertes protein, tsg-6, seine dna und verwendung
US5445940A (en) * 1991-08-28 1995-08-29 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease

Also Published As

Publication number Publication date
AU3403795A (en) 1996-03-04
EP0772456A1 (de) 1997-05-14
DE69534100T2 (de) 2006-03-23
EP0772456A4 (de) 1999-06-30
JPH10503656A (ja) 1998-04-07
CA2196776A1 (en) 1996-02-15
DE69534100D1 (de) 2005-04-28
AU700490B2 (en) 1999-01-07
WO1996004019A1 (en) 1996-02-15
US5639600A (en) 1997-06-17
EP0772456B1 (de) 2005-03-23

Similar Documents

Publication Publication Date Title
ATE291614T1 (de) Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen
CY1122817T1 (el) Νεα αντι-il 13 αντισωματα και χρησεις αυτων
BR9912053A (pt) Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
TNSN05300A1 (en) Treatment with anti-vegf antibodies
ES2148171T3 (es) Gen mutado en cancer colorrectal de humanos.
ES2158115T3 (es) Derivados de histidina y homohistidina como inhibidores de la farnesiltransferasa de proteinas.
NO20002979D0 (no) Undersøkelse av human papillomavirus-relatert sykdom
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
ATE435281T1 (de) Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
DE59611341D1 (de) Verwendung von saccharid-konjugaten
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
WO2005054295A3 (en) Therapeutic and diagnostic anti-hsp 70 antibodies
DE69911380D1 (de) Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen
DE60005952D1 (de) Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten
AU2002251754A1 (en) Therapeutic modulation of the tumor inflammatory response
HUP0300007A2 (en) Antibody with specificity for colon cancer
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
AU2003229876A1 (en) Tumour associated antigens
ATE291620T1 (de) Mammakarzinom-assoziiertes gen
MD2419G2 (ro) Metodă de tratament al tumorilor maligne local răspândite
EP4384278A4 (de) Antimetastatisches mittel, das auf prostatakrebszellen wirksam ist und zur verwendung bei der behandlung dieser erkrankungen geeignet ist

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties